One of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company.

Every program at Recursion is a product of our Recursion OS. With every new discovery, our platform gets smarter, leading to pipeline growth.

Our programs target diseases spanning several therapeutic areas where:


1. the cause of the disease is well-defined

2. there is high unmet need, there are no approved therapies, or there are significant shortcomings with existing treatment paradigms

Expanded Access Policy
Phase 1

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

Familial Adenomatous Polyposis

GM2 Gangliosidosis

Preclinical

Clostridium difficile Colitis

Pulmonary Arterial Hypertension

Immune checkpoint resistance in STK11-mutant NSCLC

Senolytics

Late Discovery

Neuroinflammation

Oncology
(small molecule
MYC Inhibitors)

Cancer Immunotherapy Target Alpha

Cancer Immunotherapy Target Beta

Hepatocellular carcinoma

Charcot-Marie-Tooth Disease Type 2

Batten Disease

Early Discovery

41 Early Discovery Programs

Phase 2
Phase 3
Commercial
Disease Model
Early Discovery
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

Solid Tumors

Dilated Cardiomyopathy

Clostridium difficile Colitis

Neuroinflammation

Batten Disease

Charcot-Marie-Tooth Disease

Pulmonary Arterial Hypertension

Lung Disease

Senescence

Vascular Disease

+ 18 early
discovery programs

Oncology 1

Oncology 2

Phase 1

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

*Undisclosed indication

Disease Indication
Early Discovery
Late Discovery
Preclinical
Phase 1
Phase 2
Commercial
Neurofibromatosis Type 2
Cerebral Cavernous Malformation
Familial Adenomatous Polyposis
GM2 Gangliosidosis
Clostridium difficile Colitis
Immune checkpoint resistance in STK11-mutant NSCLC
Pulmonary Arterial Hypertension
Senolytics
Neuroinflammation
Oncology
(small molecule 
MYC Inhibitors)
Cancer Immunotherapy Target Alpha
Cancer Immunotherapy Target Beta
Hepatocellular carcinoma
Charcot-Marie-Tooth Disease Type 2
Batten Disease
41 Early Discovery Programs
18

Early Discovery

Metabolic Disorders
Tumor Suppression
Cancers
Mitochondrial Diseases
Lysosomal Storage Disorders
Nervous System Disorders
Neurodevelopment Disorders
Neurodegenerative Disorders
Inflammation

4

Discovery

Lung Disease
Senescence
Vascular Dysplasia
Tumor Suppression

6

Preclinical

Dialated Cardiomyophathy
Clostridium Difficile Colitis
Amitrophic Lateral Sclerosis
Batten Disease
Charcot-Marie-Tooth Disease
Pulmonary Arterial Hypertension

3

Phase 1

Neurofibromatosis Type 2
Cerebral Cavernous Malformation
*Undisclosed indication

Welcome to the era of industrialized drug discovery.

Proud founding member of BioHive, the fastest growing life sciences community in the nation

Get In Touch

41 S Rio Grande Street
Salt Lake City, UT 84101
phone: (385) 269-0203
fax: (801) 821-2872
info@recursion.com
Investor Relations

Connect

LinkedIn
Twitter
Youtube